Venturi Wealth Management LLC Invests $136,000 in United Therapeutics Co. (NASDAQ:UTHR)

Venturi Wealth Management LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 385 shares of the biotechnology company’s stock, valued at approximately $136,000.

Several other large investors also recently modified their holdings of the stock. CIBC Asset Management Inc increased its stake in shares of United Therapeutics by 4.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,598 shares of the biotechnology company’s stock worth $564,000 after purchasing an additional 65 shares during the last quarter. Nkcfo LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $132,000. Principal Securities Inc. increased its stake in shares of United Therapeutics by 14.2% during the 4th quarter. Principal Securities Inc. now owns 2,174 shares of the biotechnology company’s stock worth $767,000 after purchasing an additional 270 shares during the last quarter. AustralianSuper Pty Ltd increased its stake in shares of United Therapeutics by 577.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after purchasing an additional 161,751 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in shares of United Therapeutics by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the biotechnology company’s stock worth $4,375,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on UTHR shares. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Activity

In related news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the transaction, the director now owns 5,051 shares in the company, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 124,164 shares of company stock worth $45,398,793. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

United Therapeutics stock opened at $361.10 on Friday. The firm’s fifty day moving average price is $362.68 and its 200-day moving average price is $360.45. The stock has a market cap of $16.12 billion, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $214.75 and a fifty-two week high of $417.82.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.